Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, Rowe SM, Clancy JP, Konstan MW, Hoch HE, Heltshe SL, Ramsey BW, Campbell PW, Ashlock MA.

J Cyst Fibros. 2014 Mar;13(2):139-47.

2.

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group.

PLoS One. 2013 Jul 26;8(7):e66955. doi: 10.1371/journal.pone.0066955. Print 2013.

3.

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R; VX08-770-103 (ENVISION) Study Group.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC.

4.

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group.

Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672.

5.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

6.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW.

N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.

7.

Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients.

Bakkal S, Robinson SM, Ordonez CL, Waltz DA, Riley MA.

Microbiology. 2010 Jul;156(Pt 7):2058-67. doi: 10.1099/mic.0.036848-0. Epub 2010 Apr 8.

8.

Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays.

Montor WR, Huang J, Hu Y, Hainsworth E, Lynch S, Kronish JW, Ordonez CL, Logvinenko T, Lory S, LaBaer J.

Infect Immun. 2009 Nov;77(11):4877-86. doi: 10.1128/IAI.00698-09. Epub 2009 Sep 8.

9.

A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus.

Mougous JD, Cuff ME, Raunser S, Shen A, Zhou M, Gifford CA, Goodman AL, Joachimiak G, Ordoñez CL, Lory S, Walz T, Joachimiak A, Mekalanos JJ.

Science. 2006 Jun 9;312(5779):1526-30.

10.

The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB.

J Infect Dis. 2005 Dec 1;192(11):2012-9. Epub 2005 Nov 1.

PMID:
16267775
12.

Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.

Ordoñez CL, Kartashov AI, Wohl ME.

J Pediatr. 2004 Nov;145(5):689-92.

PMID:
15520781
13.

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML.

Am J Respir Crit Care Med. 2003 Dec 15;168(12):1471-5. Epub 2003 Sep 11.

PMID:
12969869
14.

Epithelial desquamation in asthma.

Ordoñez CL, Fahy JV.

Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1997. No abstract available.

PMID:
11780603
15.

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.

Ordoñez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA.

Pediatr Pulmonol. 2001 Jul;32(1):29-37.

PMID:
11416873
16.

Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression.

Ordoñez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, Hotchkiss JA, Zhang Y, Novikov A, Dolganov G, Fahy JV.

Am J Respir Crit Care Med. 2001 Feb;163(2):517-23.

PMID:
11179133
17.

Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance.

Ordoñez CL, Shaughnessy TE, Matthay MA, Fahy JV.

Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1185-90.

PMID:
10764310
18.

Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells.

Longphre M, Li D, Gallup M, Drori E, Ordoñez CL, Redman T, Wenzel S, Bice DE, Fahy JV, Basbaum C.

J Clin Invest. 1999 Nov;104(10):1375-82.

Supplemental Content

Loading ...
Support Center